South China Morning Post

AstraZeneca, Merck, Novo deals boost Chinese biotech as global interest grows

Shares of Akeso surged after British drug maker AstraZeneca moved to advance the Chinese biotech firm’s flagship cancer drug, while a new deal from US giant Merck further underscored the sector’s global momentum amid easing fears of US curbs. AstraZeneca on Tuesday announced a US$2 billion equity investment in Florida-headquartered Summit Therapeutics, which holds the exclusive rights to develop and commercialise Akeso’s immunotherapy drug ivonescimab outside China. Summit and AstraZeneca would.

Por South China Morning Post

1 minuto de lectura
AstraZeneca, Merck, Novo deals boost Chinese biotech as global interest grows
AstraZeneca, Merck, Novo deals boost Chinese biotech as global interest grows

¿Tiene noticias que compartir con el sector de eventos?

Envíe un comunicado de prensa o una noticia y llegue a miles de profesionales del sector de eventos.

Contáctenos→

Más en Startups & Entrepreneurship

Perspectivas relacionadas